PineTree Therapeutics key facts
as of Oct 2026- Developer of biological therapeutics technology designed to treat unmet needs in oncology and infectious diseases.
- PineTree Therapeutics is valued at approximately $358.0M as of Oct 2026 (last reported valuation).
- It has raised $97.5M.
- Notable investors include Korea Investment Partners, Smilegate Investment, InterVest, STIC Ventures, Schmidt (South Korea) — 19 tracked in total.
- Status: Privately Held (backing).
PineTree Therapeutics's last reported valuation, Aug 2025. Nothing priced has surfaced since.
- ·The complete investor list: 19 names
- ·Watch PineTree Therapeutics: the Monday email on marks, rounds and moves
PineTree Therapeutics funding rounds
No funding rounds for PineTree Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs PineTree Therapeutics
19+PineTree Therapeutics valuation
PineTree Therapeutics's last reported valuation was $358 million in Aug 2025. No priced round, secondary trade or fund mark has surfaced since.
PineTree Therapeutics investors
19 investors are on record for PineTree Therapeutics, including Korea Investment Partners, Smilegate Investment, InterVest and STIC Ventures. By type, the record holds 8 venture capital firms.
About PineTree Therapeutics
Developer of biological therapeutics technology designed to treat unmet needs in oncology and infectious diseases. The company utilizes tumor-associated essential receptor-targeting antibody and virus-targeting recombinant agent platforms for infectious disease technology, enabling medical professionals to develop an anticancer drug for solid cancer patients.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2019
- Employees
- 35
- Website
- pinetreetx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.